Improvements in both investigator- and patient-reported outcomes were observed at 12 months of treatment with #tralokinumab for #AtopicDermatitis, with no new safety signals identified.

Read more: https://www.dermatologyadvisor.com/news/real-world-results-confirms-efficacy-safety-tralokinumab-ad/